Rhythm Pharmaceuticals Investor Relations Material

Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for rare genetic disorders related to obesity. The company’s primary area of focus is on conditions caused by impairments in the melanocortin-4 receptor (MC4R) pathway, which regulates hunger and body weight. Rhythm Pharmaceuticals aims to address unmet medical needs by developing targeted therapies that can help manage severe obesity and related symptoms in patients with specific genetic deficiencies. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.